By Sherri Oslick --
About Court Report: Each week we will report briefly on recently filed biotech and pharma cases.
Bayer CropScience AG v. Dow Agrosciences LLC
1:10-cv-01045; filed December 3, 2010 in the District Court of Delaware
Infringement of U.S. Patent No. 6,153,401 ("Microorganisms and Plasmids for 2,-4-Dichlorophenocyacetic Acid (2,4-D) Monooxygenase Formation and Process for the Production of These Plasmids and Strains," issued November 28, 2000) based on Dow's manufacture, use, sale, and offer for sale of transgenic plants and/or seeds resistant to 2,4-D herbicide. View the complaint here.
Medicis Pharmaceutical Corp. v. Aurobindo Pharma Ltd. et al.
1:10-cv-01050; filed December 3, 2010 in the District Court of Delaware
• Plaintiff: Medicis Pharmaceutical Corp.
• Defendants: Aurobindo Pharma Ltd.; Aurobindo Pharma USA Inc.
Infringement of U.S. Patent Nos. 5,908,838 ("Method for the Treatment of Acne," issued June 1, 1999) and 7,790,705 ("Minocycline Oral Dosage Forms for the Treatment of Acne," issued September 7, 2010) following a Paragraph IV certification as part of Aurobindo's filing of an ANDA to manufacture a generic version of Medics' Solodyn® (minocycline hydrochloride extended release tablets, used to treat acne). View the complaint here.
Novartis Pharmaceuticals Corp. v. Aurobindo Pharma Ltd. et al.
3:10-cv-06283; filed December 3, 2010 in the District Court of New Jersey
• Plaintiff: Novartis Pharmaceuticals Corp.
• Defendants: Aurobindo Pharma Ltd.; Aurobindo Pharma USA, Inc.
Infringement of U.S. Patent No. 6,162,802 ("Synergistic Combination Therapy Using Benazepril and Amlodipine for the Treatment of Cardiovascular Disorders and Compositions Therefor," issued December 19, 2000) following a Paragraph IV certification as part of Aurobindo's filing of an ANDA to manufacture a generic version of Novartis' Lotrel® (amlodipine besylate/benazepril hydrochloride, used to treat hypertension). View the complaint here.
Hoffmann-La Roche Inc. v. Apotex Inc. et al.
2:10-cv-06241; filed December 2, 2010 in the District Court of New Jersey
• Plaintiff: Hoffmann-La Roche Inc.
• Defendants: Apotex Inc.; Apotex Corp.
Infringement of U.S. Patent No. 7,718,634 ("Method of Treatment Using Bisphosphonic Acid," issued May 18, 2010) following a Paragraph IV certification as part of Apotex's filing of an ANDA to manufacture a generic version of Roche's Boniva® (ibandronate sodium, used to treat post-menopausal osteoporosis). View the complaint here.
Comments